Read Time:11 Second
Merck’s stock was headed lower in early trading Tuesday, after the drugmaker reported second-quarter profit and sales that beat expectations, amid strength in sales of cancer treatment Keytruda, but provided a mixed full-year outlook.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
